Compare · ABT vs ENVB
ABT vs ENVB
Side-by-side comparison of Abbott Laboratories (ABT) and Enveric Biosciences Inc. (ENVB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ENVB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $157.63B, about 24464.8x ENVB ($6.4M).
- Over the past year, ABT is down 32.2% and ENVB is down 88.8% - ABT leads by 56.6 points.
- ENVB has been more active in the news (12 items in the past 4 weeks vs 6 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 3 for ENVB).
- Company
- Abbott Laboratories
- Enveric Biosciences Inc.
- Price
- $90.44-0.69%
- $1.75-1.13%
- Market cap
- $157.63B
- $6.4M
- 1M return
- +4.00%
- -43.91%
- 1Y return
- -32.20%
- -88.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 12
- Recent ratings
- 25
- 3
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Enveric Biosciences Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest ENVB
- Chief Financial Officer Coveney Kevin Michael was granted 133,333 shares, increasing direct ownership by 281% to 180,746 units (SEC Form 4)
- Chief Executive Officer Tucker Joseph Edward was granted 201,124 shares, increasing direct ownership by 286% to 271,479 units (SEC Form 4)
- Director Pasqualone Frank was granted 18,518 shares, increasing direct ownership by 234% to 26,423 units (SEC Form 4)
- Director Webb Michael D was granted 18,518 shares, increasing direct ownership by 234% to 26,416 units (SEC Form 4)
- Director Schabacker Marcus was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)
- Director Kegler George A. was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)
- Director Dewitt Sheila was granted 18,518 shares, increasing direct ownership by 238% to 26,306 units (SEC Form 4)
- Chief Innovation Officer Facchini Peter J. was granted 25,000 shares, increasing direct ownership by 907% to 27,755 units (SEC Form 4)
- Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
- SEC Form S-8 filed by Enveric Biosciences Inc.